phase III trial

A phase III trial is the large, expensive, definitive study that a drug must usually win before a regulator will allow it onto the market. Where phase II hinted that a drug helps, phase III is meant to prove it convincingly, in numbers large enough that the result is hard to dismiss as luck.

These trials enroll hundreds to thousands of patients, often across many hospitals and countries, and are typically randomized, controlled, and blinded so neither patients nor doctors know who received the drug. They compare the candidate against placebo or against the existing standard of care, measuring a predefined primary endpoint — survival, hospitalization, a hard clinical outcome — agreed with regulators in advance. Their large size lets them detect modest but real benefits and surface uncommon side effects that smaller studies missed. Because of this, phase III trials are often called pivotal trials.

Phase III is where the most money is at stake and where a late, costly failure does the most damage. A drug can pass phases I and II and still fail here if the benefit shrinks in a larger, more representative population, or if a rare serious harm finally appears. Success in phase III is the central evidence behind a marketing application, but even then approval is a regulator's judgment, not an automatic consequence.